ID   T47D/182R-2
AC   CVCL_1D35
SY   T47D-182R2; 182R-2
DR   cancercelllines; CVCL_1D35
DR   CancerTools; 151890
DR   ECACC; 16022508
DR   Wikidata; Q54971572
DR   Ximbio; 151890
RX   PubMed=24513268;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:31638; Fulvestrant (ICI 182780).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu194Phe (c.580C>T); ClinVar=VCV000127817; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): ECACC
ST   Amelogenin: X
ST   CSF1PO: 11,13
ST   D13S317: 12
ST   D16S539: 10
ST   D18S51: 17
ST   D21S11: 28,31
ST   D3S1358: 15,17
ST   D5S818: 12
ST   D7S820: 11
ST   D8S1179: 13
ST   FGA: 23
ST   Penta D: 10,12
ST   Penta E: 7,14
ST   TH01: 6
ST   TPOX: 11
ST   vWA: 14
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1D46 ! T47D/S5
SX   Female
AG   54Y
CA   Cancer cell line
DT   Created: 08-07-15; Last updated: 05-10-23; Version: 15
//
RX   PubMed=24513268; DOI=10.1016/j.canlet.2013.10.014;
RA   Kirkegaard T., Hansen S.K., Larsen S.L., Reiter B.E., Sorensen B.S.,
RA   Lykkesfeldt A.E.;
RT   "T47D breast cancer cells switch from ER/HER to HER/c-Src signaling
RT   upon acquiring resistance to the antiestrogen fulvestrant.";
RL   Cancer Lett. 344:90-100(2014).
//